ArticleCureus2023
Investigating the Impact of COVID-19 Vaccines on Liver Function: Insights From a Single-Institute Study.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Diabetic Mice Spleen Vulnerability Contributes to Decreased Persistence of Antibody Production after SARS-CoV-2 Vaccine.International journal of molecular sciences · 2024Article
- Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction.Toxicologic pathology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction SARS-CoV-2 can cause respiratory and extrapulmonary complications, including liver injury. Therefore, understanding the virus's impact on the liver and the coronavirus disease 2019 (COVID-19) vaccine's protective effect is crucial, given the correlation between hepatic involvement and disease severity. Our study aims to evaluate this relationship and the impact of vaccination on liver injury in COVID-19-infected patients. Methods A retrospective cohort study analyzed liver function outcomes in COVID-19-infected patients who received two doses of the Pfizer-BioNTech or Moderna mRNA vaccine from October 2019 to October 2021. The study population was matched based on baseline characteristics, and Fisher's T-test was used for analysis. Secondary outcomes included COVID-19-related death, hospital stay, and SARS-CoV-2 infection after the second dose. SPSS (IBM Corp., Armonk, NY) and RStudio (RStudio, PBC, Boston, USA) software were utilized to ensure robust statistical analysis. Results A group of 78 patients with a propensity score were matched and analyzed, resulting in two groups of 39 patients each: vaccinated and unvaccinated. The vaccinated group had a lower incidence of liver injury, reduced length of stay, and mortality. The study suggests that COVID-19 vaccination can positively impact infected patients. These findings should be considered when making decisions about vaccine distribution and usage, and more research is needed to fully understand the vaccine's impact on ending the pandemic. Conclusion This study emphasizes the COVID-19 vaccine's significance in reducing liver injury and related outcomes, such as length of stay and mortality in infected patients. The results provide further evidence of vaccination benefits, with implications for healthcare professionals and policymakers. Further research is needed to deepen our understanding of COVID-19's complex effects on the liver and the vaccine's impact. Investing in research can inform clinical management, improve patient outcomes, and ultimately help end the pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.